Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Northstar49on Feb 26, 2020 4:39pm

368 Views

Post# 30737733

Ryan Modesto discusses (ATE) Antibe Therapeutics

Ryan Modesto, CEO at 5I Research discusses his outlook for shares of Antibe Therapeutics on BNN Market Call this afternoon.

"The market is watching" as he put it.
I am "Holding" for up.

https://www.bnnbloomberg.ca/market-call/ryan-modesto-discusses-antibe-therapeutics~1909329

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season